Marcaine Adrenaline (Epinephrine, Bupivacaine Hydrochloride, Anhydrous)

Bupivacaine hydrochloride blocks voltage‑gated sodium channels on nerve fibers, inhibiting the initiation and conduction of action potentials. This interruption prevents pain signals from reaching the brain, resulting in a reversible loss of sensation in the targeted area.

The specific dose of Marcaine Adrenaline is determined by the prescribing clinician based on the type of procedure, patient weight, and clinical setting. Healthcare professionals calculate the appropriate volume and concentration to stay within recommended safety limits.

Safety data for Marcaine Adrenaline in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Marcaine Adrenaline combines bupivacaine with epinephrine, which causes local vasoconstriction. This addition prolongs the anesthetic effect, reduces systemic absorption, and can decrease intra‑operative bleeding compared with plain bupivacaine, which lacks the vasoconstrictive component.

Marcaine Adrenaline should be stored at ambient temperature, below 25 °C, protected from light and moisture, and kept in its original packaging. Do not freeze the solution, and inspect the vial for particulate matter before use.

The product is supplied as a sterile solution for injection and is administered by a qualified practitioner via epidural or infiltration techniques. Proper aseptic technique and accurate dosing are essential to achieve the desired anesthetic effect and minimize toxicity.

Serious risks include cardiac arrhythmias, severe hypotension, seizures, and anaphylactic reactions. These events are rare but require immediate medical attention. Monitoring of cardiovascular and neurologic status during and after administration is recommended.

Patients with known hypersensitivity to bupivacaine, epinephrine, or other amide‑type local anesthetics should avoid this product. It is also contraindicated in individuals with uncontrolled hypertension, significant cardiac conduction disorders, or certain severe systemic illnesses where regional anesthesia is unsafe.